Valuation: Grifols, S.A.

Capitalization 5.58B 6.55B 5.16B 4.86B 9.06B 609B 9.24B 60.59B 23.71B 293B 24.58B 24.06B 1,042B P/E ratio 2026 *
11.2x
P/E ratio 2027 * 8.27x
Enterprise value 13.97B 16.4B 12.93B 12.18B 22.68B 1,525B 23.14B 152B 59.36B 733B 61.55B 60.25B 2,610B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.62x
Free-Float
79.4%
Yield 2026 *
2.17%
Yield 2027 * 2.95%
1 day+0.61%
1 week-2.93%
Current month-0.25%
1 month-8.18%
3 months-21.56%
6 months-24.38%
Current year-16.50%
1 week 8.79
Extreme 8.794
9.57
1 month 8.43
Extreme 8.432
9.68
Current year 8.43
Extreme 8.432
11.7
1 year 7.98
Extreme 7.978
13.7
3 years 6.36
Extreme 6.362
15.92
5 years 6.36
Extreme 6.362
25.94
10 years 6.36
Extreme 6.362
34.31
Manager TitleAgeSince
Chief Executive Officer 57 01/04/2024
Chief Tech/Sci/R&D Officer 52 01/09/2024
Comptroller/Controller/Auditor 47 01/01/2016
Director TitleAgeSince
Chairman 76 25/01/2010
Director/Board Member 70 13/04/2000
Director/Board Member 62 24/05/2015
Change 5d. change 1-year change 3-years change Capi.($)
+0.61%-2.93%+13.38%-3.31% 6.55B
-2.47%-1.70%+37.06%-9.09% 76.85B
+1.18%+3.97%+104.23%+219.62% 61.45B
-0.57%+57.10%+57.10%+57.10% 49.05B
-0.74%+0.19%-42.43%-53.63% 47.32B
-2.34%-2.46%+52.56%-38.85% 25.38B
-0.62%+3.58%+108.00%-68.18% 20.21B
+0.85%-3.28%+102.52%+130.77% 19.61B
-0.92%+0.15%+74.13%+29.95% 19.12B
+1.04%+1.35%+62.09%+61.96% 15.18B
Average -0.40%+0.33%+56.86%+32.63% 34.07B
Weighted average by Cap. -0.68%+0.97%+52.89%+43.29%

Financials

2026 *2027 *
Net sales 7.81B 9.17B 7.23B 6.81B 12.68B 853B 12.94B 84.81B 33.18B 410B 34.41B 33.68B 1,459B 8.33B 9.77B 7.71B 7.26B 13.51B 909B 13.79B 90.4B 35.37B 437B 36.68B 35.9B 1,555B
Net income 536M 630M 497M 467M 871M 58.57B 889M 5.82B 2.28B 28.13B 2.36B 2.31B 100B 734M 861M 679M 639M 1.19B 80.11B 1.22B 7.97B 3.12B 38.47B 3.23B 3.16B 137B
Net Debt 8.39B 9.85B 7.77B 7.31B 13.62B 916B 13.9B 91.11B 35.65B 440B 36.97B 36.19B 1,568B 7.94B 9.32B 7.35B 6.92B 12.89B 867B 13.16B 86.24B 33.74B 416B 34.99B 34.25B 1,484B
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (85.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (3%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (2.9%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.9%), European Union (15.5%), the United States and Canada (56.7%) and other (21.9%).
Employees
25,258
Date Price Change Volume
10/04/26 8.934 +0.61% 2,889,963
09/04/26 8.880 -5.93% 7,383,256
08/04/26 9.440 +4.33% 3,299,293
07/04/26 9.048 -1.69% 2,463,741
02/04/26 9.204 -0.71% 1,803,941
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
8.934EUR
Average target price
14.96EUR
Spread / Average Target
+67.48%

Quarterly revenue - Rate of surprise